Skip to search boxSkip to navigationSkip to main content

Efficient transduction of human hematopoietic cells with the human multidrug resistance gene I via SV40 pseudovirions

  • Deborah Rund(corresponding author)
    ,
  • Michal Dagan
    ,
  • Nava Dalyot-Herman
    ,
  • Chava Kimchi-Sarfaty
    ,
  • ,
  • Michael M. Gottesman
*Corresponding author for this work
  • Hadassah University Medical Centre
    ,
  • The Hadassah-Hebrew University School of Medicine
    ,
  • ,
  • National Institutes of Health
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Transduction of MDR1 may be of use in chemoprotection of normal bone marrow (BM) cells during treatment of malignancies, or as a selectable marker for the transfer of other genes into the BM, a critical target for the cure of many diseases. To that aim, the human multidrug resistance gene MDR1 was cloned into an SV40 pseudoviral vector containing the SV40 origin of replication (ori) and encapsidation signal (ses), and the plasmid was encapsidated in COS cells as SV40/MDR1 pseudovirions. Expression of the human MDR1 gene was demonstrated in murine MEL cells infected with SV40/MDR1 pseudovirions, using a monoclonal antibody (MPK16) specific for the human 170-kD P-glycoprotein. Functional P-glycoprotein was demonstrated by resistance to colchicine in NIH-3T3 cells infected with SV40/MDR1 pseudovirions. Activity of P-glycoprotein was assayed by rhodamine-123 dye exclusion and fluorescence-activated cell sorter analysis (FACS) in various cell types including hematopoietic cells. Highly efficient gene transfer and expression was demonstrated in all murine and human cell types tested, including primary human BM cells. Using multiplicities of infection (moi) of 1-2, over 95% of cells were found to become MDR1+. The percent of MDR1+ cells was proportional to the moi. We conclude that the SV40 pseudoviral vector is efficient for gene transmission into human hematopoietic cells.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 649-657 (9 pages)

Journal (Volume, Issue Number)

Human Gene Therapy (Volume 9, Issue 5)

Publication milestones

  • Published - 03/20/1998

Publication status

Published - 03/20/1998

ISSN

1043-0342

Publication IDs

  • Scopus: 0032549686
  • PubMed: 9551613

Publication metrics

Metrics

SciVal
citations
37
SciVal
FWCI
1.47
SciVal
Author count
7
SciVal
Paper percentile
82
Scopus
citations
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
11
Citation count
40